山村 隆 やまむら たかし 先生

来歴等

略歴

1980年 京都大学医学部 卒業
1980年 京都大学医学部付属病院老年科・神経内科 研修医
1981年 財団法人住友病院神経内科 医員
1984年 国立武蔵療養所神経センター（現：NCNP） 研究員
1987年 西独Max-Planck研究所 留学
1989年 Harvard大学神経内科 留学
1990年 国立精神・神経研究センター疾病研究第六部 室長
1999年 国立精神・神経医療研究センター神経研究所免疫研究部 部長
2010年 国立精神・神経医療研究センター多発性硬化症センター センター長
2015年 国立精神・神経医療研究センター神経研究所 特任研究部長

論文

• Trial of Satralizumab in neuromyelitis optica spectrum disorder. New Engl J Med 381: 2114-2124, 2019

  Yamamura, T., I. Kleiter, K. Fujihara, J. Palace, B. Greenberg, B. Zakrzewska-Pniewska, F. Patti, C.-P. Tsai, A. Saiz, H. Yamazaki, Y. Kawata, P.Wright, and J. De Seze

• Gut microbiota-dependent CCR9+CD4+ T cells are altered in secondary progressive multiple sclerosis. Brain 142: 916-931, 2019 Feb 15 doi: 10.1093/brain/awz012.

  Kadowaki, A., R. Saga, Y. Lin, W. Sato, and T.Yamamura

• Application of immunotherapy for neurological manifestations in hypermobile Ehlers-Danlos syndrome. Ther Adv Neurol Disord Aug 18;11:1756286418793766. doi: 10.1177/1756286418793766. eCollection 2018

  Araki, M., Y. Lin, H. Ono, W. Sato, and T.Yamamura

• Normal brain imaging accompanies neuroimmunologically justified, autoimmune encephalomyelitis. Neurology: Neuroimmunology Neuroinflammation. 2018 Apr 2;5(3):e456. doi: 10.1212/NXI.00000000000004

  Takewaki, D., Y. Lin, W. Sato, H. Ono, M. Nakamura, M. Araki, T. Okamoto, Y. Takahashi, Y. Kimura, M. Ota, N. Sato, and T.Yamamura

• Circulating esoxomes suppress the induction of regulatory T cells via let-7i in multiple sclerosis. Nat Commun 17, 2018 DOI:10.1038/S41467-017-02406-2

  Kimura, K., H. Hohjoh, M. Fukuoka, W. Sato, S. Oki, C. Tomi, H. Yamaguchi, T. Kondo, R. Takahashi, and T.Yamamura

• Gut environment-induced intraepithelial autoreactive CD4+ T cells suppress central nervous system autoimmunity via LAG-3. Nat Commun 7:11639. Doi: 10.1038/ncomms11639

  Kadowaki, A., S. Miyake, R. Saga, A. Chiba, H. Mochizuki, and T.Yamamura

• Eomesodermin-expressing T-helper cells are essential for chronic neuroinflammation. Nat Commun 6:8437, 2015

  Raveney, J.E.B., S. Oki, H. Hohjoh, M. Nakamura, W. Sato, M. Murata, and T.Yamamura

• Dysbiosis in the Gut Microbiota of Patients with Multiple Sclerosis, with a Striking Depletion of Species Belonging to Clostridia XIVa and IV Clusters. PLOS ONE 10: e0137429, 2015.

  Miyake, S., S. Kim, W. Suda, K. Oshima, M. Nakamura, T. Matsuoka, N. Chihara, A. Tomita, W. Sato, S.W. Kim, H. Morita, M. Hattori, and T.Yamamura

• Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: A pilot study. Neurology 82: 1302-1306, 2014

  Araki, M., T. Matsuoka, K. Miyamoto, S. Kusunoki, T. Okamoto, M. Murata, S. Miyake, T. Aranami, and T.Yamamura

• Plasmablasts as migratory IgG producing cells in the pathogenesis of neuromyelitis optica. PLOS One 8 (12): e83036, 2013

  Chihara, N., T. Aranami, S. Oki, T. Matsuoka, M. Nakamura, H. Kishida, K. Yokoyama, Y. Kuroiwa, N. Hattori, T. Okamoto, M. Murata, T. Toda, S. Miyake, and T.Yamamura

• Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. PNAS 108：3701-3706, 2011

  Chihara, N., T. Aranami, W. Sato, Y. Miyazaki, S. Miyake, T. Okamoto, M. Ogawa, T. Toda, and T.Yamamura

• NKT cell-dependent amelioration of a mouse model of multiple sclerosis by altering gut flora. Am J Pathol 173: 1714-1723, 2008

  Yokote, H., S. Miyake, J.L. Croxford, S. Oki, H. Mizusawa, and T.Yamamura

• Orphan nuclear receptor NR4A2 expressed in T cells from multiple sclerosis mediates production of inflammatory cytokines. Proc Natl Acad Sci U S A 105: 8381-8386, 2008

  Doi, Y., S. Oki, T. Ozawa, H. Hohjoh, S. Miyake, and T.Yamamura

• The regulatory role of natural killer cells in multiple sclerosis. Brain 127: 1917-1927, 2004

  Takahashi, K., T. Aranami, M. Endoh, S. Miyake, and T.Yamamura

• A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 413:531-534, 2001

  Miyamoto, K., S. Miyake, and T.Yamamura

• Natural killer type 2 (NK2) bias in remission of multiple sclerosis. J Clin Invest 107:R23-R29, 2001

  Takahashi, K., S. Miyake, T. Kondo, K. Terao, M. Hatakenaka, S. Hashimoto and T.Yamamura

著書

• 山村　隆　編集. 診断と治療者　2012年　　多発性硬化症（MS）診療のすべて

• Yamamura T & Gran B. (Edits) / Springer 2013 Multiple Sclerosis Immunology. A foundation for current and future treatments.

その他

• 【受賞】2019年　日本免疫学会第６回ヒト免疫研究賞

• 【受賞】2020年　International Society of Neuroimmunology (ISNI) Dale E. McFarlin Memorial lecture

• 【国際シンポジウム招待講演】Yamamura T: Neuromyelitis optica spectrum disorders: Treatment paradigms in 2020 and beyond. Symposium-3 Current and emerging therapeutic approaches. 12th PACTRIMS. Singapore, 2019.11.15

• 【国際シンポジウム招待講演】Yamamura T, Kleiter I, Fujihara K, Palace　J, Greenberg　B, Zakrzewska-Pniewska　B, Patti　Ching-Piao Tsai　F, Saiz　A, Terada　Y,　 Kawata　Y, Wright　P, 　and De Seze　J. A double-blind placebo-controlled study of satralizumab (SA237), a recycling anti-IL-6 receptor monoclonal antibody, as add-on therapy for neuromyelitis optica spectrum disorder (NMOSD). Late breaking session. ECTRIMS 2018, Berlin, Germany, 2018.10.12

• 【国際シンポジウム招待講演】Yamamura, T.: Asia. Parallel Session. Prevalence and phenotype evolution in different continents. 7th Joint ECTRIMS-ACTRIMS Meeting (MSParis 2017), Paris, France, 2017.10.25

• 【国際シンポジウム招待講演】Yamamura, T.: Anti-IL6 Receptor Monoclonal Antibody Therapy in NMO. PACTRIMS 2015. Seoul. 2015.11.19